Recent News

• 04.24.2025 - Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia
• 04.23.2025 - Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
• 04.21.2025 - Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
• 04.14.2025 - Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
• 04.02.2025 - Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
• 03.26.2025 - Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
• 03.03.2025 - Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
• 02.28.2025 - Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
• 02.26.2025 - Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
• 02.19.2025 - Inside Nexalin: CEO Mark White on TBI Solutions & Expanding Market Potential

Recent Filings

• 04.23.2025 - S-3 Registration statement under Securities Act of 1933
• 04.17.2025 - 8-K Current report
• 04.15.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.31.2025 - DRS Draft Registration Statement
• 03.14.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.10.2025 - 5 Annual statement of changes in beneficial ownership of securities